Expanded Access to AgenT-797 in Severe ARDS Reinforces Clinical Efficacy; Data Highlighted at ATS 2024 Annual Meeting Phase 2 Study in 2L Gastric Cancer Advances; Early Clinical Data to be Presented at Upcoming Medical Conference Phase 1 Study in GvHD on Track for Activation in 2Q 2024 NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invaria ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immunemediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:3 ...

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immunemediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:3 ...

On July 23, 2024, MiNK received notice from NASDAQ confirming that the Company has satisfied the MVLS requirement as set forth in Nasdaq Listing Rule 5550(b)(2). Accordingly, the Company now satisfies the MVLS requirement for continued listing on the NASDAQ Capital Market and the matter is now closed. Investor Contact Media Contact NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinicalstage biopharmaceutical company pioneering the discovery, development, and commercial ...

MiNK Therapeutics, Inc. (INKT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street ...

To participate in the Annual Shareholders Meeting, shareholders should visit NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical- stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 12, 2024, and will be condu ...

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical- stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at the American Thoracic Society (ATS) Annual Meeting. These translationa ...

财务数据和关键指标变化 - 公司现金余额为5.8百万美元,这是在收到之前提到的新投资资金之前 [31] - 2024年第一季度经营活动现金流出为2.5百万美元,相比2023年同期的4.4百万美元有所下降 [31] - 2024年第一季度净亏损为3.8百万美元或每股0.11美元,相比2023年同期的5.7百万美元或每股0.17美元有所下降 [31] 各条业务线数据和关键指标变化 - 公司正在推进其领先的两个项目AgenT-797和MiNK-215的临床进展 [10] - AgenT-797正在进行II期胃癌临床试验,并在严重呼吸窘迫症方面取得进展 [17][19] - MiNK-215是公司发现管线的领头项目,最近在AACR会议上展示了在结直肠癌肝转移模型中的积极疗效数据 [13][14][25][26][27][28] 各个市场数据和关键指标变化 - 公司正关注FAP表达的实体瘤,特别是结直肠癌和非小细胞肺癌,这些是MiNK-215的潜在适应症 [48][49] - 结直肠癌是50岁以下男性的主要死因,女性中排名第二,是一个迫切需要有效治疗的领域 [14] 公司战略和发展方向及行业竞争 - 公司正专注于加速其iNKT细胞平台和项目的发展,包括临床阶段项目和发现阶段的领先项目 [20] - 公司正在扩大内部iNKT细胞制造能力,为2024年AgenT-797在肺部呼吸窘迫症和胃癌II期试验取得进展做准备 [20] - 公司正在加快MiNK-215的临床前开发,计划在2025年初提交IND申请,并在今年内生产临床用药物 [29] 管理层对经营环境和未来前景的评论 - 公司通过提高制造效率、战略性基础设施调整以及外部非稀释性融资,成功将运营费用降低45%以上 [11] - 公司获得了一笔5.8百万美元的新投资,将用于加快推进MiNK-215的发展 [12] - 公司对iNKT细胞在癌症和其他免疫相关疾病中的潜力保持坚定的承诺 [21] 问答环节重要的提问和回答 问题1 **Emily Bodnar 提问** - 胃癌II期试验的患者入组情况如何?每个治疗组的预期患者数量是多少? [36] - 鉴于本季度运营费用大幅下降,公司当前的管线重点和发展方向是什么? [36] **Jennifer Buell 回答** - 胃癌II期试验的患者入组进展顺利,公司没有具体披露每个治疗组的患者数量,但会有足够的患者数量来评估安全性和疗效 [37][38][39][40][41][42][43][44] - 公司将重点推进胃癌II期试验和急性呼吸窘迫症的临床开发,这些项目获得了外部非稀释性融资支持,有利于控制公司的运营费用 [40][41][42][43][44] 问题2 **Jack Allen 提问** - MiNK-215在哪些实体瘤适应症上开展临床开发?公司如何考虑临床开发策略? [47] - 公司在急性呼吸窘迫症和移植物抗宿主病项目的外部融资进展如何? [49][52] **Jennifer Buell 和 Dhan Chand 回答** - MiNK-215将重点关注FAP表达的肿瘤,特别是结直肠癌和非小细胞肺癌,这些是目前的重点适应症 [48][49][58][59] - 公司正在推进急性呼吸窘迫症的外部融资支持的随机对照II期试验,预计将在本周内完成合同谈判 [52] - 移植物抗宿主病项目仍在设计中,公司正在寻求外部融资支持,但目前暂时无法投入资金开展 [53] 问题3 **Matthew Phipps 提问** - MiNK-215是否需要与其他疗法联合使用,还是可以单药疗效足够?[56] **Dhan Chand 回答** - 基于临床前数据,MiNK-215预计具有单药疗效,可以直接杀伤FAP表达的肿瘤细胞和肿瘤相关成纤维细胞,从而促进T细胞浸润,在一些对BOT/BAL耐药的肿瘤中也可以增强疗效 [59][60]

EXHIBIT 99.1 MiNK Reports First Quarter 2024 Results NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune- mediated diseases, today announced results for the first quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the r ...

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical- stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced results for the first quarter 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. "This quarter w ...